Cancer Research and Treatment

Original Articles

Rare cancer

Clinical Features of Li-Fraumeni Syndrome in Korea: Ran Song, Sun-Young Kong, Wonyoung Choi, Eun-Gyeong Lee, Jaeyeon Woo, Jai Hong Han, Seeyoun Lee, Han-Sung Kang, So-Youn Jung; Cancer Res Treat. 2024;56(1):334-341. Published online August 9, 2023; DOI: https://doi.org/10.4143/crt.2023.794

Abstract PDF Supplementary Material PubReader ePub

Purpose
Li-Fraumeni syndrome (LFS) is a hereditary disorder caused by germline mutation in TP53. Owing to the rarity of LFS, data on its clinical features are limited. This study aimed to evaluate the clinical characteristics and prognosis of Korean patients with LFS.
Materials and Methods
Patients who underwent genetic counseling and confirmed with germline TP53 mutation in the National Cancer Center in Korea between 2011 and 2022 were retrospectively reviewed. Data on family history with pedigree, types of mutation, clinical features, and prognosis were collected.
Results
Fourteen patients with LFS were included in this study. The median age at diagnosis of the first tumor was 32 years. Missense and nonsense mutations were observed in 13 and one patients, respectively. The repeated mutations were p.Arg273His, p.Ala138Val, and pPro190Leu. The sister with breast cancer harbored the same mutation of p.Ala138Val. Seven patients had multiple primary cancers. Breast cancer was most frequently observed, and other types of tumor included sarcoma, thyroid cancer, pancreatic cancer, brain tumor, adrenocortical carcinoma, ovarian cancer, endometrial cancer, colon cancer, vaginal cancer, skin cancer, and leukemia. The median follow-up period was 51.5 months. Two and four patients showed local recurrence and distant metastasis, respectively. Two patients died of leukemia and pancreatic cancer 3 and 23 months after diagnosis, respectively.
Conclusion
This study provides information on different characteristics of patients with LFS, including types of mutation, types of cancer, and prognostic outcomes. For more appropriate management of these patients, proper genetic screening and multidisciplinary discussion are required.

Citations

Citations to this article as recorded by

Consensus Statement: Recommendations on Actionable Biomarker Testing for Thyroid Cancer Management
Ozgur Mete, Andrée Boucher, Kasmintan A. Schrader, Omar Abdel-Rahman, Houda Bahig, Cheryl Ho, Olfat Kamel Hasan, Bernard Lemieux, Eric Winquist, Ralph Wong, Jonn Wu, Nicole Chau, Shereen Ezzat
Endocrine Pathology.2024;[Epub] CrossRef

3,265 View
191 Download
1 Crossref

General

Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients: Wonyoung Choi, Yun-Hee Kim, Sang Myung Woo, Yebeen Yu, Mi Rim Lee, Woo Jin Lee, Jung Won Chun, Sung Hoon Sim, Heejung Chae, Hyoeun Shim, Keun Seok Lee, Sun-Young Kong; Cancer Res Treat. 2023;55(4):1077-1086. Published online June 12, 2023; DOI: https://doi.org/10.4143/crt.2022.1630

Abstract PDF Supplementary Material PubReader ePub

Purpose
Patient-derived tumor cells can be a powerful resource for studying pathophysiological mechanisms and developing robust strategies for precision medicine. However, establishing organoids from patient-derived cells is challenging because of limited access to tissue specimens. Therefore, we aimed to establish organoids from malignant ascites and pleural effusions.
Materials and Methods
Ascitic or pleural fluid from pancreatic, gastric, and breast cancer patients was collected and concentrated to culture tumor cells ex vivo. Organoids were considered to be successfully cultured when maintained for five or more passages. Immunohistochemical staining was performed to compare the molecular features, and drug sensitivity was assayed to analyze the clinical responses of original patients.
Results
We collected 70 fluid samples from 58 patients (pancreatic cancer, n=39; gastric cancer, n=21; and breast cancer, n=10). The overall success rate was 40%; however, it differed with types of malignancy, with pancreatic, gastric, and breast cancers showing 48.7%, 33.3%, and 20%, respectively. Cytopathological results significantly differed between successful and failed cases (p=0.014). Immunohistochemical staining of breast cancer organoids showed molecular features identical to those of tumor tissues. In drug sensitivity assays, pancreatic cancer organoids recapitulated the clinical responses of the original patients.
Conclusion
Tumor organoids established from malignant ascites or pleural effusion of pancreatic, gastric, and breast cancers reflect the molecular characteristics and drug sensitivity profiles. Our organoid platform could be used as a testbed for patients with pleural and peritoneal metastases to guide precision oncology and drug discovery.

Citations

Citations to this article as recorded by

PRMT1 promotes pancreatic cancer development and resistance to chemotherapy
Bomin Ku, David Eisenbarth, Seonguk Baek, Tae-Keun Jeong, Ju-Gyeong Kang, Daehee Hwang, Myung-Giun Noh, Chan Choi, Sungwoo Choi, Taejun Seol, Hail Kim, Yun-Hee Kim, Sang Myung Woo, Sun-Young Kong, Dae-Sik Lim
Cell Reports Medicine.2024; 5(3): 101461. CrossRef
Establishment and Advancement of Pancreatic Organoids
Dong Hyeon Lee
Keimyung Medical Journal.2024; 43(1): 3. CrossRef
Organoid as a promising tool for primary liver cancer research: a comprehensive review
Xuekai Hu, Jiayun Wei, Pinyan Liu, Qiuxia Zheng, Yue Zhang, Qichen Zhang, Jia Yao, Jingman Ni
Cell & Bioscience.2024;[Epub] CrossRef
The use of organoids in creating immune microenvironments and treating gynecological tumors
Ling-Feng Zhou, Hui-Yan Liao, Yang Han, Yang Zhao
Journal of Translational Medicine.2024;[Epub] CrossRef
Organoid: Bridging the gap between basic research and clinical practice
Guihu Weng, Jinxin Tao, Yueze Liu, Jiangdong Qiu, Dan Su, Ruobing Wang, Wenhao Luo, Taiping Zhang
Cancer Letters.2023; 572: 216353. CrossRef

4,863 View
480 Download
4 Web of Science
5 Crossref

Lung Cancer

The Clinical Impact of Capmatinib in the Treatment of Advanced Non–Small Cell Lung Cancer with MET Exon 14 Skipping Mutation or Gene Amplification: Wonyoung Choi, Seog-Yun Park, Youngjoo Lee, Kun Young Lim, Minjoung Park, Geon Kook Lee, Ji-Youn Han; Cancer Res Treat. 2021;53(4):1024-1032. Published online January 29, 2021; DOI: https://doi.org/10.4143/crt.2020.1331

Abstract PDF Supplementary Material PubReader ePub

Purpose
Capmatinib, an oral MET kinase inhibitor, has demonstrated its efficacy against non–small cell lung cancer (NSCLC) with MET dysregulation. We investigated its clinical impact in advanced NSCLC with MET exon 14 skipping mutation (METex14) or gene amplification.
Materials and Methods
Patients who participated in the screening of a phase II study of capmatinib for advanced NSCLC were enrolled in this study. MET gene copy number (GCN), protein expression, and METex14 were analyzed and the patients’ clinical outcome were retrospectively reviewed.
Results
A total of 72 patients were included in this analysis (group A: GCN ≥ 10 or METex14, n=14; group B: others, n=58). Among them, 13 patients were treated with capmatinib (group A, n=8; group B, n=5), and the overall response rate was 50% for group A, and 0% for group B. In all patients, the median overall survival (OS) was 20.2 months (95% confidence interval [CI], 6.9 to not applicable [NA]) for group A, and 11.3 months (95% CI, 8.2 to 20.3) for group B (p=0.457). However, within group A, median OS was 21.5 months (95% CI, 20.8 to NA) for capmatinib-treated, and 7.5 months (95% CI, 3.2 to NA) for capmatinib-untreated patients (p=0.025). Among all capmatinib-untreated patients (n=59), group A showed a trend towards worse OS to group B (median OS, 7.5 months vs. 11.3 months; p=0.123).
Conclusion
Our data suggest that capmatinib is a new compelling treatment for NSCLC with MET GCN ≥ 10 or METex14 based on the improved survival within these patients.

Citations

Citations to this article as recorded by

EGFR and PI3K Signalling Pathways as Promising Targets on Circulating Tumour Cells from Patients with Metastatic Gastric Adenocarcinoma
Ann-Katrin Piper, Chelsea Penney, Jacqueline Holliday, Gary Tincknell, Yafeng Ma, Sarbar Napaki, Klaus Pantel, Daniel Brungs, Marie Ranson
International Journal of Molecular Sciences.2024; 25(10): 5565. CrossRef
Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives
Hang Zhang, Yingying Zhang, Yingying Zhu, Tian Dong, Zheng Liu
Frontiers in Oncology.2024;[Epub] CrossRef
Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents
Bassam Abu Thaher, Ihab Al-Masri, Kanan Wahedy, Rami Morjan, Saeb Aliwaini, Iman Mahmoud Al atter, Aayat Ahmed Elmabhouh, Areej khaled AL ibwaini, Saba Luay Alkhaldi, Basem Qeshta, Claus Jacob, Hans-Peter Deigner
Naunyn-Schmiedeberg's Archives of Pharmacology.2023; 396(8): 1797. CrossRef
RNA splicing alterations in lung cancer pathogenesis and therapy
Yueren Yan, Yunpeng Ren, Yufang Bao, Yongbo Wang
Cancer Pathogenesis and Therapy.2023; 1(4): 272. CrossRef
Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
Caixia Ding, Yanyi Qiu, Juan Zhang, Wei Wei, Hongbian Gao, Yong Yuan, Xiaomin Wang
BMC Pulmonary Medicine.2023;[Epub] CrossRef
Long-Term Efficacy, Safety, and Subgroup Analysis of Savolitinib in Chinese Patients With NSCLCs Harboring MET Exon 14 Skipping Alterations
Shun Lu, Jian Fang, Xingya Li, Lejie Cao, Jianying Zhou, Qisen Guo, Zongan Liang, Ying Cheng, Liyan Jiang, Nong Yang, Zhigang Han, Jianhua Shi, Yuan Chen, Hua Xu, Helong Zhang, Gongyan Chen, Rui Ma, Sanyuan Sun, Yun Fan, Songhua Fan, Jie Yu, Puhan Lu, Xia
JTO Clinical and Research Reports.2022; 3(10): 100407. CrossRef
HPLC with Fluorescence and Photodiode Array Detection for Quantifying Capmatinib in Biological Samples: Application to In Vivo and In Vitro Studies
Aref Zayed, Sana’a A. Jaber, Jomana Al Hroot, Sahar Hawamdeh, Nehad M. Ayoub, Nidal A. Qinna
Molecules.2022; 27(23): 8582. CrossRef
Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study
Bo Mi Ku, Sungwon Park, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Yoon-La Choi, Myung-Ju Ahn
Precision and Future Medicine.2022; 6(4): 233. CrossRef
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
Matthew Z Guo, Kristen A Marrone, Alexander Spira, David M Waterhouse, Susan C Scott
OncoTargets and Therapy.2021; Volume 14: 5321. CrossRef

6,863 View
277 Download
10 Web of Science
9 Crossref

Immunogenicity and Optimal Timing of 13-Valent Pneumococcal Conjugate Vaccination during Adjuvant Chemotherapy in Gastric and Colorectal Cancer: A Randomized Controlled Trial: Wonyoung Choi, Jong Gwang Kim, Seung-Hoon Beom, Jun-Eul Hwang, Hyun-Jung Shim, Sang-Hee Cho, Min-Ho Shin, Sin-Ho Jung, Ik-Joo Chung, Joon Young Song, Woo Kyun Bae; Cancer Res Treat. 2020;52(1):246-253. Published online July 9, 2019; DOI: https://doi.org/10.4143/crt.2019.189

Abstract PDF Supplementary Material PubReader ePub

Purpose
Pneumococcal vaccination (13-valent pneumococcal conjugate vaccine [PCV13]) is recommended to cancer patients undergoing systemic chemotherapy. However, the optimal time interval between vaccine administration and initiation of chemotherapy has been little studied in adult patients with solid malignancies.
Materials and Methods
We conducted a prospective randomized controlled trial to evaluate whether administering PCV13 on the first day of chemotherapy is non-inferior to vaccinating 2 weeks prior to chemotherapy initiation. Patients were randomly assigned to two study arms, and serum samples were collected at baseline and 4 weeks after vaccination to analyze the serologic response against Streptococcus pneumoniae using a multiplexed opsonophagocytic killing assay.
Results
Of the 92 patients who underwent randomization, 43 patients in arm A (vaccination 2 weeks before chemotherapy) and 44 patients in arm B (vaccination on the first day of chemotherapy) were analyzed. Immunogenicity was assessed by geometric mean and fold-increase of post-vaccination titers, seroprotection rates (percentage of patients with post-vaccination titers > 1:64), and seroconversion rates (percentage of patients with > 4-fold increase in post-vaccination titers). Serologic responses to PCV13 did not differ significantly between the two study arms according to all three types of assessments.
Conclusion
The overall antibody response to PCV13 is adequate in patients with gastric and colorectal cancer during adjuvant chemotherapy, and no significant difference was found when patients were vaccinated two weeks before or on the day of chemotherapy initiation.

Citations

Citations to this article as recorded by

Italian oncologists and vaccinations against infectious diseases: Results of a survey of the Italian Association of Medical Oncology
Angioletta Lasagna, Antonella Brunello, Nicola Silvestris, Paolo Pedrazzoli, Massimo Di Maio, Saverio Cinieri
Tumori Journal.2024; 110(1): 60. CrossRef
Vaccination of Adults With Cancer: ASCO Guideline
Mini Kamboj, Kari Bohlke, Deana M. Baptiste, Kieron Dunleavy, Abbey Fueger, Lee Jones, Amar H. Kelkar, Lisa Y. Law, Kristine B. LeFebvre, Per Ljungman, Eric D. Miller, Larissa A. Meyer, Heather N. Moore, Heloisa P. Soares, Randy A. Taplitz, Edom S. Woldet
Journal of Clinical Oncology.2024; 42(14): 1699. CrossRef
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)
P. Pedrazzoli, A. Lasagna, I. Cassaniti, A. Piralla, A. Squeri, R. Bruno, P. Sacchi, F. Baldanti, M. Di Maio, G.D. Beretta, S. Cinieri, N. Silvestris
ESMO Open.2023; 8(3): 101215. CrossRef
Pneumococcal Vaccination in Adults: A Narrative Review of Considerations for Individualized Decision-Making
Kay Choong See
Vaccines.2023; 11(5): 908. CrossRef
Uptake of vaccination in older Indian patients with cancer: A cross-sectional observational study
Tabitha M. Sabu, Vanita Noronha, Abhijith R. Rao, Anita Kumar, Shreya Gattani, Anant Ramaswamy, Anupa Pillai, Ratan Dhekale, Renita Castelino, Sharath Kumar, Arshiya Sehgal, Pallavi Rana, Vikram Gota, Rajendra Badwe, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2023; 6(1): 52. CrossRef
Review of Vaccination Recommendations in Guidelines for Non-Communicable Diseases with Highest Global Disease Burden among Adults 75 Years Old and Above
Abdul Rahman Ishak, Yu Chun Hsieh, Harshitha Srinivasan, Kay Choong See
Vaccines.2023; 11(6): 1076. CrossRef
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
Melissa Bersanelli, Elena Verzoni, Alessio Cortellini, Raffaele Giusti, Lorenzo Calvetti, Paola Ermacora, Marilena Di Napoli, Annamaria Catino, Valentina Guadalupi, Giorgia Guaitoli, Vieri Scotti, Francesca Mazzoni, Antonello Veccia, Pamela Francesca Gugl
eClinicalMedicine.2023; 61: 102044. CrossRef
Immunological Assessment of Recent Immunotherapy for Colorectal Cancer
Subhadeep Das, Diptikanta Acharya
Immunological Investigations.2023; 52(8): 1065. CrossRef
Vaccination anti-infectieuse : pour qui ? Quand ? Comment ?
M. Lachâtre, M. Murris-Espin, J. Mazières
Revue des Maladies Respiratoires Actualités.2023; 15(2): 2S209. CrossRef
Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial
Laurie Spehner, Emeline Orillard, Antoine Falcoz, Quentin Lepiller, Adeline Bouard, Hamadi Almotlak, Stefano Kim, Elsa Curtit, Guillaume Meynard, Marine Jary, Charlee Nardin, Kamal Asgarov, Syrine Abdeljaoued, Ugo Chartral, Virginie Mougey, Myriam Ben Khe
BMJ Oncology.2023; 2(1): e000054. CrossRef
Novel Pneumococcal Protein-Polysaccharide Conjugate Vaccine Based on Biotin-Streptavidin
Mengze Guo, Xiaonan Guo, Chenxing Zhang, Shidong Zhu, Yue Zhang, Tiejun Gu, Wei Kong, Yongge Wu, Nancy E. Freitag
Infection and Immunity.2022;[Epub] CrossRef
COVID-19 vaccination in cancer patients: a narrative review
Suranjith L Seneviratne, Pamodh Yasawardene, Widuranga Wijerathne, Buddhika Somawardana
Journal of International Medical Research.2022;[Epub] CrossRef
Invasive pneumococcal disease among adults with hematological and solid organ malignancies: A population-based cohort study
Hannah M. Garcia Garrido, Mirjam J. Knol, Jarom Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis
International Journal of Infectious Diseases.2021; 106: 237. CrossRef
Can Cancer Survivors Donate Convalescent Plasma for the Treatment of COVID-19?
Ajit Venniyoor
Indian Journal of Medical and Paediatric Oncology.2021; 42(01): 021. CrossRef
Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment
M. Peeters, L. Verbruggen, L. Teuwen, G. Vanhoutte, S. Vande Kerckhove, B. Peeters, S. Raats, I. Van der Massen, S. De Keersmaecker, Y. Debie, M. Huizing, P. Pannus, K. Neven, K.K. Ariën, G.A. Martens, M. Van Den Bulcke, E. Roelant, I. Desombere, S. Angui
ESMO Open.2021; 6(5): 100274. CrossRef
Recent Topics of Pneumococcal Vaccination: Indication of Pneumococcal Vaccine for Individuals at a Risk of Pneumococcal Disease in Adults
Nobuhiro Asai, Hiroshige Mikamo
Microorganisms.2021; 9(11): 2342. CrossRef
Vaccination practices, efficacy, and safety in adults with cancer
Laboni Sarkar, Vasu Babu Goli, Nandini Menon, Vijay Maruti Patil, Vanita Noronha, Kumar Prabhash
Cancer Research, Statistics, and Treatment.2021; 4(3): 505. CrossRef
Incidence of Invasive Pneumococcal Disease Among Adults With Hematological and Solid Organ Malignancies in the Netherlands: A Population Based Cohort Study
Hannah M. Garcia Garrido, Mirjam J. Knol, J. Heijmans, Nina M. van Sorge, Elisabeth A.M. Sanders, Heinz-Josef Klümpen, Martin P. Grobusch, Abraham Goorhuis
SSRN Electronic Journal .2020;[Epub] CrossRef

7,372 View
267 Download
15 Web of Science
18 Crossref

First
Prev
Page of 1
Next
Last

Search